Jennifer Boggs on Muck Rack

Jennifer Boggs

Verified
Atlanta
As seen in: BioWorld, JAMA (The Journal of the American Medical Association), Real Simple, Thomson Reuters, Annals of Internal Medicine, Healio Cardiac/Vascular Intervention, PsychiatryOnline, The Journal of Pediatrics, BioWorld MedTech
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jennifer

Contact Jennifer, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis

|
By Jennifer Boggs Verified
| BioWorld Verified
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc.
Open in Who Shared Issue with article?

Vera’s Trutakna wins FDA nod as first dual inhibitor for IgAN

|
By Jennifer Boggs Verified
| BioWorld Verified
Vera’s Trutakna wins FDA nod as first dual inhibitor for IgAN Vera Therapeutics Inc. looks to get an almost five-month head start over a competitor, Vertex Pharmaceuticals Inc., as the U.S. FDA cleared its Trutakna (atacicept) as the first dual BAFF/APRIL inhibitor for treating immunoglobulin A nephropathy (IgAN). The accelerated approval, which came on the July 7 PDUFA date, indicates Trutakna for use in reducing proteinuria in adults with primary IgAN at risk for disease progression.
Open in Who Shared Issue with article?

Orca’s T-cell therapy approach to HSCT wins FDA nod as Tregzi

|
By Jennifer Boggs Verified
| BioWorld Verified
Orca’s T-cell therapy approach to HSCT wins FDA nod as Tregzi Orca Bio Inc. is bringing to market a precision-engineered cell therapy approach designed to improve outcomes in patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) following U.S. FDA approval of Tregzi, a first-of-its-kind, personalized cell therapy. BioWorld Regulatory Hematologic Cell therapy U.S. FDA
Open in Who Shared Issue with article?
See all 519 licensed articles (520 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified